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OBJECTIVE—This study investigated the long-term effects of
intensive diabetic treatment on the progression of atherosclero-
sis, measured as common carotid artery intima-media thickness
(IMT).
RESEARCH DESIGN AND METHODS—A total of 1,116
participants (52% men) in the Epidemiology of Diabetes Inter-
ventions and Complications (EDIC) trial, a long-term follow-up of
the Diabetes Control and Complications Trial (DCCT), had
carotid IMT measurements at EDIC years 1, 6, and 12. Mean
age was 46 years, with diabetes duration of 24.5 years at EDIC
year 12. Differences in IMT progression between DCCT intensive
and conventional treatment groups were examined, controlling
for clinical characteristics, IMT reader, and imaging device.
RESULTS—Common carotid IMT progression from EDIC years
1 to 6 was 0.019 mm less in intensive than in conventional (P ,
0.0001), and from years 1 to 12 was 0.014 mm less (P = 0.048); but
change from years 6 to 12 was similar (intensive 2 conventional =
0.005 mm, P = 0.379). Mean A1C levels during DCCT and DCCT/
EDIC were strongly associated with progression of IMT, explain-
ing most of the differences in IMT progression between DCCT
treatment groups. Albuminuria, older age, male sex, smoking, and
higher systolic blood pressure were signiﬁcant predictors of IMT
progression.
CONCLUSIONS—Intensive treatment slowed IMT progression
for 6 years after the end of DCCT but did not affect IMT
progression thereafter (6–12 years). A beneﬁcial effect of prior
intensive treatment was still evident 13 years after DCCT ended.
These differences were attenuated but not negated after adjusting
for blood pressure. These results support the early initiation and
continued maintenance of intensive diabetes management in type
1 diabetes to retard atherosclerosis. Diabetes 60:607–613,
2011
T
he incidence of cardiovascular events in patients
with type 1 diabetes is high for their age (1,2),
with a prevalence of cardiovascular disease
similar to that in nondiabetic individuals who are
10 to 20 years older (3). Patients with type 1 diabetes have
increased levels of subclinical cardiovascular disease, as
measured by carotid intima-media thickness (IMT), a
measure of atherosclerosis. Carotid IMT is increased in
children, adolescents, and adults with type 1 diabetes
compared with those without diabetes (4–9).
Intensive diabetes therapy aimed at achieving glycemic
control as close to the nondiabetic range as safely possible
reduced the rate of microvascular complications in the
Diabetes Control and Complications Trial (DCCT) (10). A
trend favoring the intensive treatment group regarding
macrovascular disease (P = 0.08) (11) prompted the ad-
dition of examinations to study earlier signs of cardio-
vascular disease during the long-term observational
follow-up of the DCCT cohort (Epidemiology of Diabetes
Interventions and Complications or EDIC) (12). Coronary
artery calciﬁcation (CAC) was measured with computed
tomography during EDIC years 7 to 9. Prior intensive
treatment during DCCT was associated with lower preva-
lence of CAC .200 in the combined cohort (P = 0.026) (13).
We initially reported that intensive diabetes therapy did
not appear to inﬂuence carotid IMT measured in EDIC
year 1 (14), at a time when IMT measurements were not
signiﬁcantly different from those of age-matched and
gender-matched nondiabetic individuals. IMT measure-
ment at EDIC year 6 demonstrated that the progression of
carotid IMT was reduced in the intensive compared with
the conventional treatment group, despite comparable
A1C levels during EDIC follow-up (15). These ﬁndings
suggested that a durable effect of the differences in met-
abolic control during DCCT might play a role in athero-
sclerosis, as has been shown for microvascular
complications of diabetes (“metabolic memory”) (16–18).
The duration of this effect on atherosclerosis is unknown.
We report the 12-year follow-up of carotid IMT in the
EDIC cohort to determine the effects of glycemic control
on atherosclerosis progression in type 1 diabetes over
time. Speciﬁcally, we compared IMT progression between
the original intensive and conventional treatment groups in
the observational EDIC follow-up between years 1 and 6, 6
and 12, and during the entire 12-year period, and assessed
the association of mean A1C with IMT progression. We
also examined the risk factors for IMT progression.
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ORIGINAL ARTICLERESEARCH DESIGN AND METHODS
Participants. The 1,441 patients enrolled in the DCCT between 1983 and 1989
were aged 13 to 39 years, had had type 1 diabetes for 1 to 15 years, and were in
generally good health at baseline (10). At baseline, the primary prevention
cohort (n = 726) had no retinopathy, urine albumin excretion ,40 mg/24 h,
and diabetes duration of 1 to 5 years. The secondary intervention cohort (n =
715) had minimal to moderate nonproliferative retinopathy, urinary excretion
of albumin #200 mg/24 h, and duration of diabetes of 1 to 15 years. At the end
of the DCCT, after 6.5 years of mean follow-up, 1,375 of the 1,425 surviving
members (96%) of the original cohort volunteered to participate in EDIC (12).
During EDIC, all therapy was provided by the patients’ own physicians, and
intensive therapy was recommended for all patients. A detailed description of
EDIC procedures and baseline characteristics has been published (12).
Carotid ultrasound imaging was ﬁrst performed between June 1994 and
April 1996 (1 to 2 years after initiation of EDIC and ;8 years after the beginning
of the DCCT; range 4–11 years) (15). It was repeated between October 1998
and November 2000 in 1,229 EDIC participants. A third ultrasound study was
performed between October 2004 and April 2006. We compared IMT pro-
gression rates between EDIC visits at years 1, 6, and 12 in participants who
had all three IMT measurements, comprising 1,116 of 1,240 participants who
completed the annual EDIC year 12 examination.
Assessment of carotid IMT. IMT measurement has been described in detail
(15). A single longitudinal lateral view of the distal 10 mm of the right and left
common carotid arteries (CCAs) and three longitudinal views in different
imaging planes of each internal carotid artery (ICA) were obtained by certiﬁed
technicians at the clinical centers, recorded on S-VHS tapes, and read in
a central unit (Tufts Medical Center, Boston, MA) by two readers, masked to
treatment assignment. The current study focuses on CCA IMT measurements
because progression is more consistently measured for CCAs than for the ICA
(19,20). The three ultrasound studies for each participant were read by the
same reader within 1 month in a batch fashion (21) to guard against reader
drift in measurements. The Coordinating Center assigned the order of read-
ings. Ultrasound devices were grouped by manufacturer, model, probe imag-
ing frequency, and empiric knowledge about overall imaging characteristics. A
total of 27 combinations of imaging devices summarized equipment differ-
ences for the three study time points and the 28 centers. The maximum IMT
(millimeter) of the CCA was deﬁned as the mean of the maximum IMT for near
and far walls on both right and left sides.
Quality control procedures for IMT. Either of two readers contempora-
neously read the EDIC year 1, 6, and 12 carotid ultrasound studies, the year 1
and 6 exams being reread to ensure that the same reader read all three exams.
One read 83% of these ultrasound images and had previously read year 1 and 6
ultrasound studies for prior publications. For the common carotid IMT, the
primary reader had an intrareader coefﬁcient of reliability (intraclass corre-
lation) of .0.93 (over different periods, n = 142 pairs), and the interreader
reliability was .0.81 (n = 206 pairs). The coefﬁcients were similar for the ICA
measures (.0.93 and .0.90, respectively).
Other procedures. An annual history, physical examination, and electro-
cardiogram were obtained for each participant, as well as laboratory testing
that included determination of serum creatinine and A1C levels, as occurred
during the DCCT (10,22). The time-weighted mean A1C was computed during
the duration of the DCCT and up to speciﬁc EDIC years, with the quarterly
DCCT and annual EDIC values weighted by 3 and 12 months, respectively.
Lipid proﬁles and 4-h urine collections for measurement of albumin excretion
rate (AER; mg/24 h) and creatinine clearance were obtained in alternate years
during EDIC (12). Microalbuminuria and albuminuria were deﬁned as AER
$40 mg/24 h and AER $300 mg/24 h, respectively, at any visit during DCCT,
including at DCCT baseline, and through EDIC year 1, 6, or 12. Year 6 cova-
riates were obtained from the EDIC year 6 history and physical examination
and from the laboratory data (fasting lipids and renal function) collected in
year 5 or 6.
Statistical analyses. Groups were compared using the Wilcoxon rank sum
test for quantitative variables and the x
2 test for categoric variables. A single
general linear mixed model for repeated measurements (23–25) assessed
differences between the DCCT intensive versus conventional groups in the
CCA IMT at EDIC years 6 and 12 using an unstructured covariance matrix for
the within-subject correlation. The model adjusted for the EDIC year 1 IMT,
age, ultrasound equipment, reader, sex, and study cohort and included in-
teraction terms for treatment group by EDIC year (6 or 12 as a class effect).
Contrasts of the model coefﬁcients then provided estimates and tests of the
differences between groups in the change in carotid IMT from years 1 to 6, 1 to
12, and 6 to 12.
A multiple linear regression model (26) assessed covariate effects, including
different A1C variables, on the change in IMT from years 1 to 6 adjusted for
year 1 IMT and other factors. Another model assessed change from years 6 to
12 adjusted for year 6 IMT and risk factors; and another assessed change from
years 1 to 12 adjusted for year 1 values. In multivariate risk factor models
(years 1 to 6 and 6 to 12 only), the most signiﬁcant factor for the multivariate
association among similar variables (e.g., systolic [sBP] and diastolic blood pres-
sure) was used. Results nominally signiﬁcant at two-sided P , 0.05 were cited.
RESULTS
The baseline characteristics of the 1,116 EDIC participants
and 325 nonparticipants (without all three IMT measure-
ments) were similar except for A1C at eligibility (9.0 6
1.6% for participants and 9.4 6 1.7% for nonparticipants,
P , 0.0001). The clinical characteristics at EDIC year
6 were not signiﬁcantly different between the original
DCCT treatment groups, with the exception of albumin
excretion rates (Table 1), reﬂecting the persistent beneﬁt
of intensive treatment during DCCT. At DCCT close out,
mean A1C levels were lower in the intensive treatment
group (7.3 6 1.0% vs. 9.0 6 1.7% for women, 7.4 6 1.0% vs.
9.1 6 1.3% for men, P , 0.0001). Annual A1C levels were
minimally different (0.1–0.4 A1C %), albeit nominally sig-
niﬁcant, between treatment groups during the ﬁrst 6 years
of EDIC but not during years 7 to 12 (data not shown).
However, the weighted average over DCCT and EDIC up
to EDIC years 1, 6, and 12 each remained signiﬁcantly
different between treatment groups (Table 1). A nominally
signiﬁcant difference between treatment groups was noted
in the year 6 IMT among men but not women; however, the
group by gender interaction was not statistically signiﬁcant
(P = 0.13). Thus, further analyses were conducted for the
men and women combined.
Table 2 and Fig. 1 show the least squares means of ca-
rotid IMT progression from EDIC year 1 to years 6 and 12
from longitudinal regression models for repeated mea-
surements, adjusted for baseline factors. The progression
of IMT from EDIC years 1 to 6 was signiﬁcantly less in the
intensive compared with the conventional treatment group
(20.019 mm, P , 0.0001), as was the change from year 1 to
12 (20.014 mm, P = 0.048; Table 2, Fig. 1). However, the
difference between treatment groups in the change in IMT
from year 6 to 12 was not signiﬁcant (+0.005 mm, P =0 . 3 7 9 ) .
Similar results were obtained after adjusting for the current
sBP and LDL, but the difference between groups in the
change of carotid IMT from years 1 to 12 was no longer
nominally signiﬁcant (P =0 . 0 8 3 ) .
In the conventional treatment group, the mean change
from year 1 to 6 (0.036 mm) was nominally lower than
from year 6 to 12 (0.051 mm), but the difference was not
signiﬁcant (0.015 6 0.012 mm, P = 0.211). In the intensive
treatment group, the change in IMT from years 1 to 6 was
very minimal (0.016 mm), but the change from years 6 to
12 (0.057 mm) was signiﬁcantly greater (0.040 6 0.012 mm,
P , 0.0006) and similar to the change in the conventional
treatment group during the same time period.
Table 3 describes in the treatment groups combined the
association of the mean A1C over DCCT and during dif-
ferent periods of DCCT and EDIC, with the IMT pro-
gression adjusted for the same factors as in Table 2. The
mean A1C in DCCT and through EDIC year 1 had similar
signiﬁcant effects on the progression of IMT from year 1 to
6, whereas the EDIC mean A1C over years 1 to 6, and the
DCCT/EDIC mean through year 6 had lesser effects.
Likewise, the DCCT mean A1C and that over each sub-
sequent EDIC period had a signiﬁcant effect on the change
in IMT over year 1 to 12. The DCCT mean A1C had a lesser
effect on the change in IMT from years 6 to 12 relative to
its effects on the changes from years 1 to 6 or years 1 to 12,
in keeping with the pattern of treatment group differences
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and for years 1 to 12 had a stronger effect than that of the
DCCT mean A1C alone. Averaging the A1C over DCCT and
EDIC periods did not increase the effect of the EDIC mean
A1C alone on progression from years 6 to 12. These results
indicate that mean A1C during DCCT and EDIC up to the
year of each assessment has the strongest association with
the rate of progression in IMT up to that year.
Adjustment for the current levels of sBP and LDL over
each period (mean over 1–6, 1–12, and 6–12 years)
attenuated the association of the different DCCT and/or
EDIC A1C measures with the change in IMT over each
period, the associations with the EDIC mean A1C mea-
sures no longer being signiﬁcant. However, the associa-
tions of the DCCT mean and the DCCT/EDIC combined
mean A1C with the changes from years 1 to 6 and years
1 to 12 remained signiﬁcant, whereas the associations with
the change in IMT from years 6 to 12 were nonsigniﬁcant.
In these models, sBP was signiﬁcantly associated with IMT
progression (P , 0.0001) not LDL.
TABLE 1
Clinical characteristics of 1,116 EDIC participants with common carotid IMT measurements at years 1, 6, and 12 according to sex and
original treatment assignment
DCCT treatment groups
Women Men
Characteristics Intensive Conventional Intensive Conventional
N 267 266 296 287
Demographic, year 6
Attained age (years) 40 6 7* 39 6 74 1 6 74 1 6 6
Attained type 1 duration (years) 19 6 51 9 6 51 9 6 51 8 6 5
Smoking (%) 16.5 15.3 18.6 13.3
Medical, year 6
Body mass index $30 kg/m
2 (%) 24.3* 15.6 21.8 18.6
Systolic blood pressure (mmHg) 118 6 14 117 6 14 122 6 12 123 6 13
Diastolic blood pressure (mmHg) 74 6 97 3 6 10 77 6 97 7 6 8
Hypertension (%)† 24.9 28.6 30.5 35.1
Lipids, year 5 or 6‡
Total cholesterol (mg/dL) 190 6 33 187 6 34 192 6 38 187 6 33
HDL cholesterol (mg/dL) 63 6 16 62 6 14 51 6 13 51 6 11
LDL cholesterol (mg/dL) 111 6 30 109 6 29 119 6 30 117 6 29
Triglycerides (mg/dL) 77 6 42 76 6 47 103 6 73 98 6 73
Hyperlipidemia (%)§ 30.3 26.3 36.6 35.8
AER (mg/24 h), year 5 or 6‡
Median (1st, 3rd quartile) 10* (6, 17) 10 (6, 21) 10* (7, 16) 12 (7, 29)
Log (value [mg/24 h]) 2.3 6 0.9* 2.6 6 1.3 2.5 6 1.1* 2.9 6 1.4
$40 mg/24 h (%) 4.6* 15.2 10.7* 19.3
AER $40 or dialysis/transplant (ever)
DCCT/EDIC to years 1–2 27.7 30.8 17.6* 26.1
DCCT/EDIC to years 5–6 30.7 38 22.3* 34.8
DCCT/EDIC to years 11–12 37.1 44 30.4* 40.4
AER $300 or dialysis/transplant (ever)
DCCT/EDIC to years 1–2 3 6 3 4.9
DCCT/EDIC to years 5–6 3.0* 8.3 3.7* 10.1
DCCT/EDIC to years 11–12 4.5* 11.7 5.1* 15.7
Weighted mean A1C (%)
DCCT A1C 7.3 6 0.8* 9.1 6 1.3 7.2 6 0.8* 8.9 6 1.1
DCCT/EDIC to year 1 7.3 6 0.8* 8.9 6 1.2 7.3 6 0.9* 8.8 6 1.0
DCCT/EDIC to year 6 7.6 6 0.9* 8.6 6 1.1 7.6 6 1.0* 8.6 6 1.0
DCCT/EDIC to year 12 7.7 6 1.0* 8.3 6 1.0 7.7 6 0.9* 8.3 6 1.0
IMT year 1
Common carotid IMT (mm)
Mean 6 SD 0.601 6 0.080* 0.582 6 0.073 0.633 6 0.088 0.637 6 0.105
Median 0.592 0.578 0.627 0.625
Range (0.440–0.846) (0.414–0.787) (0.444–0.922) (0.455–1.065)
IMT year 6
Common carotid IMT (mm)
Mean 6 SD 0.613 6 0.087 0.610 6 0.096 0.647 6 0.101* 0.677 6 0.141
Median 0.602 0.6 0.636 0.646
Range (0.411–0.928) (0.417–1.121) (0.440–1.133) (0.425–1.772)
Data are means 6 SD unless noted otherwise. IMT, common intima-media thickness. *P , 0.05 by Wilcoxon rank-sum test for continuing
variables and x
2 test for categorical variables comparing conventional and intensive treatment. †Hypertension was deﬁned by a systolic blood
pressure $140 mmHg, a diastolic blood pressure $90 mmHg, documented hypertension, or the use of antihypertensive agents. ‡Renal
function and lipid levels were determined from the biennial evaluation conducted at year 5 or 6 of the EDIC study. §Hyperlipidemia was
deﬁned by an LDL cholesterol level $130 mg/dL or the use of lipid-lowering agents (physicians were alerted to the presence of hyperlipidemia
during the DCCT and the EDIC study).
J.F. POLAK AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, FEBRUARY 2011 609When the effect of intensive versus conventional ther-
apy in Table 2 is also adjusted for the DCCT mean A1C, the
F test of the treatment group effects on progression from
years 1 to 6 and years 1 to 12 are reduced by 87 and 96%,
respectively. Thus, virtually all of these long-term treat-
ment group differences in IMT progression are explained
by the differences in A1C during the DCCT.
In models adjusting for the same factors as in Table 3,
the progression of IMT from years 1 to 6 was greater by
0.013 6 0.006 mm (P = 0.031) among those with micro-
albuminuria at any time up to EDIC year 1 versus not, but
the difference among those with versus without micro-
albuminuria up to year 6 was smaller (P = 0.07). Pro-
gression from years 1 to 6 was also greater by 0.021 6 0.01
mm (P = 0.043) among those with albuminuria up to year 6
versus not, but not among those with albuminuria versus
not up to year 1 (P = 0.08). IMT progression from years 6 to
12 was greater by 0.014 6 0.007 mm (P = 0.044) among
those with microalbuminuria up to year 6, and by 0.020 6
0.006 mm (P = 0.002) with microalbuminuria up to year 12
versus not; and by 0.022 6 0.011 mm (P = 0.034) among
those with albuminuria up to year 12, but not up to year 6
(P = 0.06) versus not. However, none of these differences
in IMT progression remained signiﬁcant when also ad-
justed for the DCCT/EDIC weighted mean A1C.
The multivariable risk factor models of common carotid
IMT progression from years 1 to 6 and from years 6 to 12
(Table 4), adjusted for treatment group, explained ap-
proximately 51 and 57% of the variation in CCA IMT, re-
spectively. Lipids (LDL, HDL, total cholesterol) did not add
signiﬁcantly to the models (P . 0.10). Smoking and an
interaction of sBP and sex had signiﬁcant effects on the
change in IMT within both periods. In both models, the
male-female difference increased as sBP at the beginning
of the period increased, the difference being 0 at 104
mmHg for IMT progression from 1 to 6 years, and 109 for
IMT progression from 6 to 12 years. In both models, men
with sBP .120 mmHg (approximately) had signiﬁcantly
higher IMT progression (P = 0.05).
A BMI $30 kg/m
2 (obesity) at year 1 was not associated
with IMT progression from years 1 to 6, but BMI $30 kg/m
2
at year 6 was signiﬁcantly associated with greater IMT
progression from years 6 to 12. Because BMI differed be-
tween treatment groups, especially among women (Table
1), the two effects may be confounded. However, these
BMI effects were similar in additional models adjusted for
treatment group, or that adjusted for the DCCT/EDIC
mean A1C up to the beginning of each period. Conversely,
after adjustment for the prevalence of obesity, the effect of
the DCCT/EDIC mean A1C up to year 1 on IMT pro-
gression from years 1 to 6 was unchanged, but the effect of
the mean A1C to year 6 on IMT progression from years 6 to
12 was no longer signiﬁcant (P = 0.23).
DISCUSSION
We have shown that intensive diabetes therapy during the
DCCT had a beneﬁcial effect on IMT progression during
the entire 12 years of EDIC follow-up compared with
conventional therapy. However, although the treatment
groups differed in IMT progression from years 1 to 6 of
EDIC, they progressed at similar rates from years 6 to 12.
Thus, the beneﬁcial effects of intensive therapy at 12 years
are a reﬂection of the beneﬁts previously observed at 6
years.
These differences in carotid IMT progression between
the original DCCT treatment groups during a period when
differences in A1C levels had largely disappeared show
that a durable metabolic effect or “metabolic memory”
exists for atherosclerosis, as has been demonstrated for
microvascular disease (16,17). However, the similar IMT
progression in the original treatment groups over EDIC
years 6 to 12 support a waning of metabolic memory
(“metabolic amnesia”) over time. Nevertheless, there is no
evidence at this time of a “catch-up” effect, and the DCCT
intensive group still has a signiﬁcantly lower level of ath-
erosclerosis over the entire 12 years of EDIC.
TABLE 2
Change in least squares means* of common IMT over EDIC years 1, 6, and 12 by treatment group
Change in least squares Mean IMT difference (mm 6 SE)
EDIC period Intensive Conventional (Intensive 2 Conventional) P
Years 1 to 6 0.016 6 0.010 0.036 6 0.010 20.019 6 0.005 ,0.0001
Years 6 to 12 0.057 6 0.005 0.051 6 0.005 0.005 6 0.006 0.379
Years 1 to 12 0.072 6 0.011 0.086 6 0.010 20.014 6 0.007 0.048
*From a single general linear mixed model with effects for treatment group, age, sex, study cohort, IMT at year 1, IMT reader, image device,
EDIC year 6 or 12, and group by EDIC year interactions. Changes from years 1 to 6, 6 to 12, and 1 to 12 were estimated by contrasts among the
model coefﬁcients.
FIG. 1. Least squares means in common carotid artery IMT based on
linear mixed model adjusted for age, sex, study cohort, IMT reader,
image device, and mean baseline IMT value of 0.614 mm. A signiﬁcant
separation in mean IMT between treatment groups (intensive, ■;
conventional, ▲) emerged between years 1 and 6 (P < 0.0001) that
persisted to year 12 (P = 0.048). From years 6 to 12, the progression
rates are similar for the two treatment groups.
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cardiovascular disease, based in part on the positive
associations between carotid IMT and cardiovascular risk
factors (27). Unfortunately, it is not yet possible to de-
scribe an association between changes in IMT during EDIC
and the risk of cardiovascular events. Far too few partic-
ipants (n = 75) have experienced a cardiovascular disease
outcome event in the combined intensive and conventional
groups since the year 6 IMT was measured to provide
adequate statistical power to describe covariate effects
on cardiovascular disease risk, especially within each
group.
The associations of carotid IMT with cardiovascular risk
factors in the intensive and conventional treatment groups
were similar to those reported in other studies (28).
Carotid IMT has been used to determine the efﬁcacy of
lipid-lowering therapies in patients with cardiovascular
disease, familial hyperlipidemia, and in those with mod-
erately elevated lipid levels (29–31). Because the levels of
traditional risk factors were similar in both treatment
groups in our study, other nontraditional risk factors
should be considered as having mediated the differences
in carotid IMT. Blood glucose levels, A1C levels, and
microalbuminuria are potential mediators of carotid IMT
progression. Positive associations between blood glucose
levels and IMT have been reported in nondiabetic indi-
viduals and in type 1 and type 2 diabetic populations
(4,5,8,9,32).
A study of people with type 2 diabetes and metabolic
syndrome suggested that the component factors of the
TABLE 3
Association of mean A1C in combined treatment groups during DCCT and EDIC with change in common carotid IMT over EDIC years
1, 6, and 12*
Change in carotid intima-media thickness
Years 1 to 6 (mm) Years 6 to 12 (mm) Years 1 to 12 (mm)
Mean A1C b-coefﬁcient† P b-coefﬁcient† P b-coefﬁcient† P
DCCT 0.0074 6 0.0018 ,0.0001 0.0038 6 0.0023 0.1052 0.0087 6 0.0026 0.0008
DCCT/EDIC to year 1‡ 0.0079 6 0.0020 ,0.0001 0.0045 6 0.0025 0.0694 0.0097 6 0.0028 0.0006
EDIC years 1 to 6, mean 0.0042 6 0.0021 0.0497 0.0071 6 0.0027 0.0075 0.0084 6 0.0030 0.0049
DCCT/EDIC to year 6‡ 0.0082 6 0.0023 0.0003 0.0068 6 0.0028 0.0175 0.0115 6 0.0032 0.0003
EDIC years 1 to 12 N/A N/A 0.0083 6 0.0029 0.0039 0.0103 6 0.0032 0.0016
DCCT/EDIC to year 12‡ N/A N/A 0.0086 6 0.0031 0.0056 0.0132 6 0.0035 0.0002
N/A, not applicable. *Separate multiple linear regression models for the change in IMT over each period adjusted for age, sex, study cohort,
IMT reader, and image device. Change from years 1 to 6 and change from years 1 to 12 models also adjusted for the year 1 IMT. Change from
years 6 to 12 model also adjusted for the year 6 IMT. Separate models with each different A1C measure were performed. †The b-coefﬁcient
(estimated 6 SE) is the millimeter change in IMT progression per whole % greater A1C. ‡Weighted mean of DCCT and EDIC A1C values over
time, each weighted by the interval of time between values 3 months for each DCCT quarterly A1C value, 12 months for each EDIC annual
A1C value.
TABLE 4
Multivariate risk factor models* for progression of common IMT years 1 to 6 and 6 to 12
Change in carotid IMT (mm)
Years 1 to 6 Years 6 to 12
Risk factor (years 1 or 6)† b-coefﬁcient‡ P b-coefﬁcient‡ P
Model R
2 0.51 0.57
Attained age (years) 0.0032 6 0.0004 ,0.0001 0.0019 6 0.0005 0.0003
Sex (male vs. female) 0.0152 6 0.0055 0.0053 0.0144 6 0.0063 0.0227
Cohort (secondary vs. primary) 0.0064 6 0.0050 0.2028 0.0122 6 0.0062 0.0469
Common IMT (mm) 0.6847 6 0.0343 ,0.0001 0.8282 6 0.0328 ,0.0001
Treatment group (intensive vs. conventional) 20.0199 6 0.0051 ,0.0001 0.0024 6 0.0061 0.6921
Currently smoking (yes vs. no) 0.0173 6 0.0066 0.0088 0.0288 6 0.0084 0.0006
Systolic blood pressure (mmHg) 0.0002 6 0.0003 0.486 0.0006 6 0.0003 0.0693
Body mass index $30 kg/m
2 (yes vs. no) 0.0101 6 0.0076 0.1834 0.0224 6 0.0078 0.0043
Systolic blood pressure* sex interaction 0.0010 6 0.0004 0.0234 0.0014 6 0.0005 0.0040
Male vs. female at 100 mmHg 20.0041 6 0.0087 0.6384 20.0126 6 0.0113 0.2642
Male vs. female at 110 mmHg 0.0056 6 0.0059 0.3496 0.0009 6 0.0079 0.9094
Male vs. female at 120 mmHg 0.0152 6 0.0054 0.0053 0.0144 6 0.0063 0.0227
Male vs. female at 130 mmHg 0.0249 6 0.0078 0.0014 0.0280 6 0.0079 0.0004
Male vs. female at 140 mmHg 0.0346 6 0.0113 0.0023 0.0415 6 0.0113 0.0003
Overall effect
Sex df = 2 0.0061 df = 2 0.0012
Systolic blood pressure df = 2 0.0008 df = 2 ,0.0001
*Separate multiple linear regression models for the change in IMT over each period adjusted for readers and machine devices. In additional
models, LDL, HDL, and total cholesterol were not signiﬁcantly associated with change in IMT over either period. †The model for IMT
progression from years 1 to 6 was adjusted for risk factors evaluated or measured at EDIC year 1; the model for progression from years 6
to 12 was adjusted for factors evaluated or measured at EDIC year 6. ‡Coefﬁcient (estimated 6 SE) is the mm change in IMT progression per
unit increase in the covariate, or the difference between covariate categories as stated.
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more strongly associated with IMT than glucose levels (33).
BMI $30 kg/m
2 at year 1 was not associated with greater
IMT progression from years 1 to 6, but BMI $30 kg/m
2 at
year 6 was signiﬁcantly associated with greater IMT pro-
gression from years 6 to 12. The latter effect persisted after
adjustment for treatment group and the DCCT/EDIC mean
A1C up to year 6.
The prevalence of microalbuminuria was different be-
tween the groups, reﬂecting the long-term effects of the
original DCCT interventions. Further, a history of micro-
albuminuria, and to a lesser extent albuminuria, was as-
sociated with the changes in IMT from years 1 to 6 and
again from years 6 to 12 in the combined cohort. These
effects were not as strong as those of A1C. A previous
study of the general population showed no signiﬁcant as-
sociation between IMT and microalbuminuria (34). A study
of type 2 diabetes suggested a minor effect (35).
We have previously reported that after 11 years of EDIC
follow-up, intensive treatment therapy was associated with
a 57% reduction in major cardiovascular disease events.
This beneﬁcial effect was virtually completely explained
by the difference in A1C values between the treatment
groups during DCCT (36). We also reported that coronary
artery calciﬁcation in type 1 diabetes was signiﬁcantly
associated with mean A1C during DCCT (13). Here we
have also shown that the A1C levels are associated with
carotid IMT progression. Furthermore, the differences
between groups in the DCCT mean A1C explain a large
fraction of the long-term differences between groups in
IMT progression from years 1 to 6 and from years 1 to 12.
DCCT mean A1C was signiﬁcantly associated with IMT
change for years 1 to 6 and 1 to 12, but not years 6 to 12.
DCCT/EDIC A1C up to years 1 and 6 was strongly asso-
ciated with IMT change over years 1 to 6; DCCT/EDIC
mean A1C up to years 6 and 12 was strongly associated
with IMT change over years 6 to 12; and DCCT/EDIC mean
A1C up to years 1, 6, and 12 was strongly associated with
IMT change from years 1 to 12.
As with other microvascular and cardiovascular out-
comes in DCCT and EDIC, the cumulative glycemic ex-
posure represented by the mean A1C since entry is
strongly associated with IMT progression. A likely mech-
anism explaining the delayed effect of A1C on IMT pro-
gression may lie in the formation of long-lived advanced
glycation end products (37,38). Because the half-life of
collagen is up to 15 years, an effect on the artery wall
might take years to be seen and then to dissipate as pro-
duction of the glycation end products was affected by
glycemic control (37,38). A previously published study in
the DCCT cohort showed a predictive value for advanced
glycation end products for future complications of reti-
nopathy and nephropathy (39). A decrease in glycation of
the collagen constituents of the artery wall due to prior
differences in A1C levels during DCCT might explain the
differences in IMT progression seen at EDIC years 1 to 6.
Subcellular changes related to the differences in glycemia
may have developed during the DCCT, but their expression
as atherosclerosis and a change in IMT may have taken
longer to develop, explaining the time course we observed.
A full explanation of the pathophysiologic processes un-
derlying IMT progression awaits future investigations.
Additional analyses described here also show that
adjustments for the current levels of sBP and LDL attenuate
the group difference in and DCCT/EDIC A1C associations
with IMT progression, but do not negate them. In these
models, blood pressure, not LDL, was the signiﬁcant factor.
This indicates that the beneﬁcial effects of intensive therapy
and lower DCCT/EDIC A1C on carotid IMT during EDIC
(40) are partly mediated by beneﬁcial effects on blood
pressure and hypertension.
Limitations of this study include less-than-complete fol-
low-up of the entire DCCT cohort. In only 77% of the
original 1,441 DCCT volunteers were all three IMT scans
completed (84% of the 1,330 active EDIC participants).
However, baseline characteristics of the participants were
largely the same as those of the nonparticipants. The other
limitation was the use of different ultrasound equipment
among and within clinics over time. We included an ad-
justment for equipment in our model.
We conclude that during a period of 12 years after the
end of the DCCT intervention, progression of atheroscle-
rosis in patients with type 1 diabetes remains lower in the
original intensive than the conventional treatment group.
The beneﬁcial effect of prior intensive treatment observed
during the ﬁrst 6 years of EDIC follow-up appears to wane
during the second 6 years, although a beneﬁt of intensive
therapy persisted during the entire study period. The
overall difference in IMT progression between the two
treatment groups was observed despite similar exposure
to traditional risk factors. These long-term beneﬁts are
largely explained by the differences in A1C during the
DCCT, and the risk of progression in the entire cohort is
associated with the cumulative mean A1C reﬂecting long-
term glycemic exposure.
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